Sector News

Perrigo CFO resigns to take job at Amgen

February 28, 2017
Life sciences

A longtime member of Perrigo Co. PLC’s executive leadership team has resigned.

Judy L. Brown, who has been chief financial officer of the store-brand pharmaceuticals maker for nearly 11 years, has resigned to take another position.

While Perrigo stated that Brown “will take a position with another company in the pharmaceutical industry, beginning on April 1, 2017,” it did not name the company.

The Wall Street Journal reported online Monday that she will join California-based pharmaceutical industry giant Amgen Inc. Brown will join Amgen to run its global business services unit and its global internal audit function, the Journal reported.

It stated that she told Perrigo’s management of her decision last week.

Accounting and finance veteran Ron Winowiecki, who has been with Perrigo for about eight years, has been named acting CFO by Perrigo CEO John T. Hendrickson.

In a press release, Hendrickson praised Brown’s work, saying, “Judy’s leadership has been instrumental in developing a high caliber finance team at Perrigo and assisted our efforts to drive growth across our global platform. On behalf of the Board of Directors and management, I would like to thank Judy for her contributions to Perrigo over her more than 15-year tenure with the Company, and wish her all the best in her future endeavors.”

Brown was named executive vice president and CFO in July 2006. Oversight of business operations was added to her responsibilities in May of 2016. She was vice president and corporate controller of the company from September of 2004 to July of 2006. Prior to that, she held various senior positions in finance and operations at Whirlpool Corp.

Perrigo said in its press release that it will conduct a thorough search to identify a new permanent chief financial officer, but Winowiecki would be a “key candidate” for the position.

Winowiecki has been Perrigo’s senior vice president in business finance since January 2014. Before that, he was vice president in treasury and accounting shared services from September of 2011 to December of 2013 and was corporate vice president and treasurer from October 2008 to August 2011.

Winowiecki has a bachelor’s degree in accounting from Hope College and a master’s degree in business administration from Western Michigan University.

Speaking of Winowiecki, Hendrickson said, “Ron has almost 30 years of accounting and finance experience, devoting nearly 15 years to leading global public company finance organizations in the capacities of corporate controller, treasurer and chief accounting officer, including eight years at Perrigo, most recently as senior vice president, business finance. I am confident that this will be a seamless transition and that Ron will provide Perrigo and our financial team with strong leadership. I look forward to continuing to work alongside Ron.”

Perrigo also announced Monday that Svend Andersen has been appointed executive vice president and president of Consumer Healthcare International. The CHCI segment comprises Perrigo’s branded consumer healthcare business as well as its legacy international businesses. He will report directly to Hendrickson and join Perrigo’s executive committee.

Source: MLive

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.